Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3

Cancer Research

Volumn 64, Issue 10, 2004, Pages 3645-3652

  George, Prince ^a   Bali, Purva ^a   Cohen, Pamela ^b   Tao, Jianguo ^a   Guo, Fei ^a   Sigua, Celia ^a   Vishvanath, Anasuya ^a   Fiskus, Warren ^a   Scuto, Anna ^a   Annavarapu, Srinivas ^a   Moscinski, Lynn ^a   Bhalla, Kapil ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINODEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; CHAPERONE; FLT3 KINASE; FLT3 LIGAND; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; ONCOSTATIN M; PHOSPHOTRANSFERASE; PROTEASOME; PROTEIN KINASE B; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL STRAIN; CELL STRAIN MV4 11; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; UBIQUITINATION; WILD TYPE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CYSTEINE ENDOPEPTIDASES; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; G1 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOCYTIC, ACUTE; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RIFABUTIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STAUROSPORINE; TRANS-ACTIVATORS; UBIQUITIN;

EID: 2442695516     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0006     Document Type: Article

References (31)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
2. Stirewalt DL, Radich J. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
3. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-8.
4. Tse K-F, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia (Baltimore) 2000;14:1766-76.
5. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
6. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002;28:689-93.
7. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43.
8. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-5.
9. Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia (Baltimore) 2002;16:1535-40.
10. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483-93.
11. Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia (Baltimore) 2002;16:455-62.
12. Isaacs HS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
13. Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997;272:23843-50.
14. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of Imatinib Mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35.
15. Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin (17-AAG). Cancer Res 2002;62:5761-9.
16. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804.
17. Fang G, Kim C, Perkins C, et al. CGP57148 (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-56.
18. L overexpression inhibits Taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 1996;7:1087-94.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
20. L, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003;102:269-75.
21. Mizuki M, Schwäble J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-73.
22. Dosil M, Wang S, Lemischka IR. Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993;13:6572-85.
23. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003;9:2140-50.
24. Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000;192:719-28.
25. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3:173-83.
26. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003;102:646-51.
27. Estey EH, Fisher T, Giles F, et al. A randomized Phase 11 trial of the tyrosine kinase inhibitor PKC412 in patients (pt) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3 [abstract]. Blood 2003;102:2270.
28. Solit DB, Anana M, Valentin G, et al. Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (pt) with advanced cancer [abstract]. Proc Am Soc Clin Oncol 2003;22:795.
29. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002;100:3041-4.
30. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice. Anticancer Res 2003;23:1395-9.
31. Jia W, Yu C, Rahmani M, et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003;102:1824-32.